![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/regenerx-effects-reverse-stock-split-and-terminates-sec-reporting-obligations-301900639.html
https://www.prnewswire.com/news-releases/regenerx-receives-stockholder-approval-for-reverse-stock-split-301895000.html
https://www.prnewswire.com/news-releases/regenerx-to-extend-consent-solicitation-vote-301890689.html
https://www.prnewswire.com/news-releases/first-patient-enrolled-into-us-phase-3-neurotrophic-keratitis-clinical-trial-with-rgn-259-301796701.html
https://www.prnewswire.com/news-releases/regenerx-issues-letter-to-stockholders-301794921.html
https://www.prnewswire.com/news-releases/publication-of-rgn-259-phase-3-clinical-trial-results-in-patients-with-neurotrophic-keratopathy-301712318.html
https://www.prnewswire.com/news-releases/regenerx-licensee-submits-special-protocol-assessment-to-fda-for-4th-phase-3-clinical-trial-for-dry-eye-disease-301657406.html
https://www.prnewswire.com/news-releases/regenerx-partner-submits-phase-3-protocol-for-neurotrophic-keratopathy-nk-301634537.html
https://www.prnewswire.com/news-releases/regenerx-issues-2022-letter-to-stockholders-301609278.html
https://www.prnewswire.com/news-releases/regenerx-partner-signs-loi-with-global-ophthalmology-cro-for-two-phase-3-clinical-trials-in-neurotrophic-keratitis-301588063.html